- Anixa Biosciences has partnered with CDMO Curia to develop the formulation for its investigational breast cancer vaccine ahead of a planned Phase 2 clinical trial.
- The vaccine completed a Phase 1 trial involving 35 women, with 74% demonstrating protocol-defined immune responses and a favorable safety and tolerability profile.
Anixa Biosciences has selected contract development and manufacturing organization (CDMO) Curia to provide formulation development services for its investigational breast cancer vaccine as the company prepares for Phase 2 clinical development. The vaccine is being developed in collaboration with Cleveland Clinic.
Under the collaboration, Curia will develop a formulation intended to optimize the vaccine’s stability, consistency, and suitability for clinical manufacturing. The work will also address analytical performance, scalability, and aseptic manufacturing requirements. The companies aim to establish a formulation and development process that can support future clinical studies and potential commercial production.
The investigational vaccine is designed to stimulate the immune system to recognize alpha-lactalbumin, a protein expressed in many breast cancers. Anixa recently completed a Phase 1 clinical trial involving 35 women. The study met its primary endpoints and demonstrated a favorable safety and tolerability profile, with 74% of participants exhibiting protocol-defined immune responses. The company is preparing to advance the vaccine into Phase 2 to further evaluate its potential clinical benefits.
“Our Phase 1 trial demonstrated encouraging safety and immune-response results, and we are now focused on the activities necessary to support the next stage of clinical testing.”
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences
Curia will provide formulation development expertise to support the vaccine’s progression through clinical manufacturing preparations.